Purple Biotech Ltd (PPBT)
NASDAQ: PPBT · Real-Time Price · USD
2.250
+0.045 (2.04%)
At close: May 12, 2025, 4:00 PM
2.160
-0.090 (-4.00%)
After-hours: May 12, 2025, 6:19 PM EDT
Purple Biotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
6.08M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
PPBT News
- 20 hours ago - Purple Biotech Appoints Shai Lankry as Chief Financial Officer - GlobeNewsWire
- 14 days ago - Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers - GlobeNewsWire
- 2 months ago - Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial - GlobeNewsWire
- 5 months ago - Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire
- 5 months ago - Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire
- 5 months ago - Why Is Purple Biotech Stock Trading Higher On Monday? - Benzinga
- 6 months ago - Purple Biotech Reports Third Quarter 2024 Financial Results - GlobeNewsWire